Evolent Q3 revenue $222.5M (-7.1% YoY); net loss $13M; board adds Dr. Tunde Sotunde

Evolent Health, Inc.

2021-Q3 EPS reported -$0.37 revenue$659,599,000

GAAP revenue $222.5M, down 7.1% YoY; revenue ex-divested assets up 36.3%.
Net loss attributable to common $13.0M; Adjusted EBITDA $13.8M.
Total lives managed 14.7M (1.6M EHS, 13.1M Clinical Solutions).
New partnerships: Sunflower Medical Group, Northern Medical Group, Health New England; 10 partner additions in 2021.
Board: Dr. Tunde Sotunde appointed; Frank Williams to non-executive Chairman effective Jan 1, 2022.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Frank Williams

non-executive Chairman

EVH · Evolent Health, Inc.

Effective: 2022-01-01
Filed: November 3, 2021, 7:59 PM ET

Additionally, on October 28, 2021, the Board and Mr. Frank Williams mutually agreed that Mr. Williams will transition from Executive Chairman to the role of non-executive Chairman of the Board, effective January 1, 2022.

Departed

Michael D’Amato

Director

EVH · Evolent Health, Inc.

Effective: 2021-10-28
Filed: November 3, 2021, 7:59 PM ET

On October 28, 2021, Mr. Michael D’Amato retired from the Company’s Board of Directors (the “ Board ”).

Appointed

Dr. Tunde Sotunde

Director

EVH · Evolent Health, Inc.

Effective: 2021-10-28
Filed: November 3, 2021, 7:59 PM ET

On October 28, 2021, the Board (1) appointed Dr. Tunde Sotunde to the Board as a Class II director with a term expiring at the 2023 Annual Meeting and (2) appointed Dr. Sotunde to the Audit Committee of the Board and the Compliance and Regulatory Affairs Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Frank Williams changed role as non-executive Chairman at Evolent Health, Inc..

Action: transition
Role: non-executive Chairman

Exact text from the filing

Additionally, on October 28, 2021, the Board and Mr. Frank Williams mutually agreed that Mr. Williams will transition from Executive Chairman to the role of non-executive Chairman of the Board, effective January 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael D’Amato retired as Director at Evolent Health, Inc..

Action: retired
Role: Director

Exact text from the filing

On October 28, 2021, Mr. Michael D’Amato retired from the Company’s Board of Directors (the “ Board ”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Tunde Sotunde was appointed as Director at Evolent Health, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 28, 2021, the Board (1) appointed Dr. Tunde Sotunde to the Board as a Class II director with a term expiring at the 2023 Annual Meeting and (2) appointed Dr. Sotunde to the Audit Committee of the Board and the Compliance and Regulatory Affairs Committee of the Board.

View on SEC.gov

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-21-000142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.